Armaviscon Intra-articular injection 1% syringe 2ml, 1pc

Composition

Composition per 1 ml: sodium hyaluronate – 9-11 mg / ml (1%), sodium chloride-8.50 mg / ml, sodium hydrophosphate dihydrate-0.28 mg / ml, sodium dihydrophosphate dihydrate-0.044 mg / ml, water for injection-up to 1 ml

Pharmacological action

Scope of application-orthopedics, rheumatology, traumatology, surgery, sports medicine. Armaviscon is a joint synovial fluid protector. It is used against the background of degenerative changes in the surface of synovial cartilage to improve joint mobility, reduce pain, reduce inflammatory reactions and restore homeostasis in the cartilage. Properties and efficacy The product has an analgesic, corrective effect on the metabolism of bone and cartilage tissue. Armaviscon is a sterile viscous solution of the sodium salt of hyaluronic acid (sodium hyaluronate) with a high degree of purification, high molecular weight. Hyaluronic acid is a necessary component of the extracellular matrix and is present in high concentrations in the cartilage and synovial fluid. Hyaluronic acid provides the viscosity and elasticity of synovial fluid, and it is also necessary for the formation of cartilage. In osteoarthritis, there is a deficiency and qualitative changes in hyaluronic acid in the composition of synovial fluid and cartilage. Intra-articular use of hyaluronic acid leads to an improvement in the functional state of the joint. When using Armaviscon for knee osteoarthritis, there is an improvement in the clinical course of 2 osteoarthritis up to six months from the moment of application, an anti-inflammatory and analgesic effect is observed due to the replenishment of the volume and restoration of the viscosity and elasticity of synovial fluid, which fills the joint cavity and acts as an intra-articular lubricant. It prevents friction of the joint surfaces, which eliminates pain and inflammation. It also protects against premature wear and destruction of hyaline cartilage, provides mobility, and has shock-absorbing properties (it dampens external shocks, protecting the joint components from damage). Sodium hyaluronate solution is distributed locally in the joint cavity, where it undergoes local transformations, exerting a lubricating effect. Removal or replacement of the drug is not applicable, since it is inseparably mixed with the synovial fluid of the joint.

Indications

• for increasing joint mobility and eliminating pain caused by degenerative-dystrophic or post-traumatic changes in the joints;
• for rehabilitation after arthroscopy;
• for the treatment of patients who have increased physical activity and regularly load the affected joint.

Recommendations for use

Intra-articular. In the knee joint, the contents of one filled syringe – 2 ml (20 mg) should be administered 1 time a week, a course of 5 injections according to the standard procedure described below. Usually, a 1.5 inch 21G needle is used for the knee joint, but for other joints, it is recommended to use a needle of the required size (from 17G to 22G), depending on the joint. Method of use The product should only be administered by medical personnel who have received special training. The mode of introduction into the hip, etc. joints are determined by the doctor individually, taking into account the severity of degenerative or traumatic changes in the joint. It is recommended to perform injections in the hip, etc. joints under ultrasound or X-ray control. It is recommended to heat the product to room temperature before use. The drug should be administered exactly into the joint cavity according to standard methods, taking into account anatomical features. Before use of the drug, the effusion from the joint bag should be removed. To remove the effusion and administer the drug, the same needle can be used, once inserted before aspiration. In this case, the syringe with the product is attached to the needle released from the syringe. To confirm that the needle is located in the joint cavity, the available amount of synovial fluid should be aspirated before slow use. Follow the rules of asepsis and antisepsis when performing the procedure. The injection of the drug into the joint cavity should be stopped if pain occurs during the injection. When inserting a needle, especially for hip injections, local anesthesia is recommended. Avoid getting air into the syringe. Unused funds are not subject to storage until the end. The duration of the therapeutic effect is up to 6 months. If necessary, it is possible to conduct a second course of injections after consulting a doctor.

Contraindications

• hypersensitivity to the components of the drug;
• the presence of infection or damage to the skin in the injection area;
• acute synovitis;
• children under 18 years of age (due to lack of clinical data).

Side effects

There may be moderate soreness, swelling, fever and redness in the injection area, an increase in the content of exudate in the joint cavity. The above symptoms are transient and usually disappear after 24 hours. If these symptoms occur, it is recommended to relieve the affected joint and apply ice. Very rarely, allergic reactions can occur.

Interaction

Armaviscone should not be administered simultaneously with other intra-articular injections, due to the lack of significant experience. Do not use disinfectants containing quaternary ammonium compounds, since hyaluronic acid precipitates in the presence of these substances.

Special instructions

Sodium hyaluronate is obtained by fermentation of Streptococcus equi bacteria and thoroughly purified. However, the doctor should consider the potential risk associated with injecting any biological substances. Extraarticular injection of Armaviscone into the joint capsule or synovial tissues is not allowed. This may cause local side effects. Do not allow the product to enter the blood vessels. During the first 2 days after the procedure, it is recommended not to overload the joint, especially avoid prolonged stress. Armaviscon does not affect a person’s ability to drive vehicles or engage in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions. Patients with inflammatory diseases, in particular, Ankylosing spondylitis and rheumatoid arthritis, Armaviscon is not prescribed. Not intended for children. Only for a single use. The kit may include 2 disposable sterile injection needles for the doctor to select the required size of the needle depending on the joint into which the product will be injected. Please observe national and regional regulations to safely use and dispose of used needles.

Storage conditions

Store at a temperature of + 2 °C to + 25 °C. Do not freeze it. Keep out of reach of children.

Shelf

life is 3 years. Do not use after the expiration date!

Active ingredient

Sodium Hyaluronate

Dosage form

solution for injection